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Abstract  
 
Background: Schwannomatosis is a recently recognized form of neurofibromatosis 
characterized by multiple non-cutaneous schwannomas, a histologically benign nerve 
sheath tumor.  As more cases are identified, the reported phenotype continues to 
expand and evolve.  We describe the spectrum of clinical findings in a cohort of patients 
meeting established criteria for schwannomatosis. 
Methods:  We retrospectively reviewed the clinical records of patients seen at our 
institution between 1995 and 2011 who fulfilled either research or clinical criteria for 
schwannomatosis.  Clinical, radiographic, and pathologic data were extracted with 
attention to age of onset, location of tumors, ophthalmologic evaluation, family history, 
and other stigmata of NF1 or NF2. 
Results: Eighty-seven patients met criteria for the study.  The most common 
presentation was pain unassociated with a mass (46%).  Peripheral schwannomas were 
present in 77/87 patients (89%), spinal schwannomas in 49/66 (74%), non-vestibular 
intracranial schwannomas in 7/77 (9%), and intracranial meningiomas in 4/77 (5%).  
Three patients were initially diagnosed with a malignant peripheral nerve sheath tumor 
(MPNST); however, following pathologic review, the diagnoses were revised in all 3 
cases.  Chronic pain was the most common symptom (68%) and usually persisted 
despite aggressive surgical and medical management.  Other common diagnoses 
included headaches, depression, and anxiety. 
Conclusions:  Peripheral and spinal schwannomas are common in schwannomatosis 
patients.  Severe pain is difficult to treat in these patients, and often associated with 
anxiety and depression.  These findings support a proactive surveillance plan to identify 
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tumors by MRI scan in order to optimize surgical treatment and to treat associated pain, 
anxiety, and depression.   
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Introduction 
Schwannomatosis is the third major form of neurofibromatosis, a group of 
neurogenetic disorders that share a predisposition to multiple nerve sheath tumors.  The 
condition was initially thought to represent a mild form of neurofibromatosis 2 (NF2) 
since early series included patients with multiple peripheral schwannomas.[1]  Research 
criteria for schwannomatosis were proposed in 1997[2], and by 2003, it was clear that 
schwannomatosis was clinically and genetically distinct from NF2.[3]  In 2005, 
consensus diagnostic criteria for schwannomatosis were adopted for clinical use[4,5] 
and were modified the following year  to specifically exclude patients who fulfill the NF2 
diagnostic criteria (with bilateral vestibular schwannomas on high-quality MRI, first-
degree relative with NF2, or a known constitutional NF2 mutation.[5]  
Schwannomatosis is uncommon, with an annual incidence of 0.58 cases per 
1,000,000 persons.[6]  As more cases are identified, the reported phenotype continues 
to expand and evolve.  For example, recent case reports indicate that meningiomas and 
malignant peripheral nerve sheath tumors (MPNST) occur in the setting of 
schwannomatosis[7,8,9,10].  Reports on the clinical findings in large cohorts of patients 
with long follow up are therefore essential for our understanding of the disease 
phenotype.  In this report, we describe the spectrum of clinical findings in 87 patients 
meeting criteria for schwannomatosis in a tertiary neurofibromatosis clinic.  
  
Methods 
 
The clinical records of patients seen at The Family Center for Neurofibromatosis 
at Massachusetts General Hospital (MGH) between 1995 and 2011 were retrospectively 
reviewed.  Patients who fulfilled either research criteria (used prior to 2005)[1], 
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consensus diagnostic criteria[4], or modified diagnostic criteria[5] for schwannomatosis 
(Table 1) were included in the study. Clinical, radiographic, and pathologic data were 
extracted from clinical records with specific attention to age of onset, location of tumors, 
ophthalmologic evaluation, family history, and other stigmata of NF1 or NF2. All patients 
were examined by a neurologist in the Neurofibromatosis clinic at MGH.  This 
retrospective study was approved by the Massachusetts General Hospital institutional 
review board (IRB). 
 
Results 
 
Diagnostic and Research Criteria 
 
Eighty-seven patients who met either research or diagnostic criteria for 
schwannomatosis were identified.  Sixty patients (69%) met research criteria for 
definite, presumptive, or probable schwannomatosis; 27 did not meet research criteria 
based on having only one pathologically proven schwannoma.  Eighty patients (92%) 
met criteria for presumptive or definite schwannomatosis based on consensus 
diagnostic criteria.  Seven patients did not meet consensus diagnostic criteria due to 
lack of high-quality MRI in a patient younger than 45.  Sixty-six patients (76%) met the 
more restrictive modified diagnostic criteria; 21 patients did not meet modified criteria 
due to lack of internal auditory canal (IAC) protocol on MRI scan.  None of the 87 
patients met diagnostic criteria for NF1 or NF2. 
 
Patient Characteristics 
 Of the 87 patients meeting research or diagnostic criteria, 46 (53%) were female. 
The median age of initial symptom was 30 years (range, 8-59 years).  The median age 
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at diagnosis was 40 years (range, 16-70 years), with a median delay from initial 
symptom to diagnosis of 7 years (range, 0-39 years).  A family history of 
schwannomatosis was present in 11 individuals (13%) from 7 different families.  Fifty 
patients (57%) initially presented with pain, including 40 (46%) unassociated with a 
mass and 10 (11%) associated with a mass.  Thirty-six patients (41%) presented with a 
mass, including 24 (27%) with a painless mass, ten with a painful mass (11%), and 2 
(2%) whose tumor was found incidentally during other imaging.  Nine patients (10%) 
experienced other symptoms such as numbness or weakness.  In 4 patients (5%), the 
presenting symptoms were unknown. 
 
Nervous system tumors 
 Among 77 patients with cranial imaging, 7 non-vestibular cranial schwannomas 
were identified in 7 patients (8%) and 5 meningiomas were identified in 4 patients (5%). 
In contrast with NF2, no vestibular schwannomas were identified.  Among 66 individuals 
with spinal imaging, spinal schwannomas were common (74%, 49/66). Spinal tumors 
were most common in the lumbar spine (53%, 35/66), followed by thoracic spine (35%, 
23/66), and cervical spine (23%, 15/66). Spinal tumors were most commonly localized 
to a single area of the spine (59%, 29/49) but in some patients involved two areas (33%, 
16/49) or the entire spine (8%, 4/49).  In contrast with NF2, no intramedullary tumors 
suggestive of ependymoma were noted.   
 Peripheral schwannomas were present in most patients (89%; 77/87 patients), 
with the arms and legs being most commonly affected (46% and 45%, respectively) 
followed by the head/neck (29%, 25/87), chest (16%, 14/87), pelvis (15%, 13/87), and 
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abdomen (9%, 8/87).  Anatomically limited disease, defined as multiple schwannomas 
limited to a single limb or 2 spinal segments (Table 1), was present in 26 (30%) patients. 
The location of segmental involvement included leg (35%), arm (23%), spine (23%), 
other (19%, e.g. pelvis). 
 
Other clinical manifestations 
 Subcutaneous masses (presumed tumors) were identified by clinical examination 
in 23% of patients (20/87) with most presenting with 1-5 masses.   In addition to 
schwannomas, pathologically proven lipomas were excised from eleven (13%) patients, 
angiolipomas from three (3%), and cutaneous neurofibroma from two (2%). 
Ophthalmologic abnormalities were present in a minority of patients who had formal 
examinations (18%, 7/39), and included single cases of visual field defect, Addis pupil, 
red/green color blindness, unilateral juvenile cataract, amblyopia, indistinct 
hyperpigmentation, and undefined ophthalmologic stigmata of neurofibromatosis.  
Twenty patients (23%) had at least 1 café-au-lait macule that was larger than 1.5 cm in 
size; no patients had more than 4.  No skin fold freckling was seen in these patients. 
Four patients had a history of learning disability (5%), 5 (6%) had an existing diagnosis 
of scoliosis, and 14 (16%) reported tinnitus. 
 
Surgical Management 
 Eighty-six patients underwent 217 surgeries for resection of schwannoma 
(median number of surgeries per patient: 2, range: 1 – 9).  Forty patients underwent a 
total of 72 spinal surgeries, including 20 on the cervical spine (28%), 11 on the thoracic 
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spine (15%), 30 on the lumbosacral spine (42%), and 11 on more than one spinal 
section (15%). Almost half of patients (18/40, 45%) experienced persistent post-
operative deficits, including sensory abnormalities in 13 patients, weakness in 4, painful 
kyphosis or kyphoscoliosis in 3, and bladder dysfunction in 3.  Seventy patients 
underwent 145 peripheral surgeries in locations spanning the entire body. Nineteen 
patients (27%, 19/70) had persistent post-operative deficits, including sensory 
abnormalities in 12 patients, weakness in 5, and bladder dysfunction in one. 
 
Prevalence and Management of Pain 
 The most common symptom reported by schwannomatosis patients was chronic 
pain (68%, 59/87 patients) which included both local and multifocal/diffuse pain.  
Sixteen patients (18%) were disabled by their pain and either had to take extended 
medical leave from work or were unable to work.  Accordingly, pain was the indication 
for surgery in most patients (80%, 70/87) and for most surgeries (80%, 145/181) for 
which an indication for surgery was documented.   Local pain was completely relieved in 
less than half of surgeries (39%, 57/145), and recurred in most patients (75%, 43/57) 
either at the site of the original tumor or due to a new tumor.  Local pain was partially 
relieved after 20/145 (14%) surgeries, and was unchanged after 41/145 (28%) 
surgeries.  The outcome on local pain relief was unknown for 27/145 (19%) surgeries.   
 Most patients (62%, 54/87) reported use of medications for chronic pain at some 
point in their care.  The median number of pain medications trialed was 3 (range, 1 to 
15) with 72% of patients (39/54) reported use of 5 or fewer medications, 20% of patients 
(11/54) reported six to ten medications, and 7% of patients (4/54) reported more than 
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ten medications.  An equal number of patients reported use of neuropathic, opiate, and 
anti-inflammatory medications 63%, (34/54), most commonly gabapentin (24/54), 
oxycodone formulations (23/54) and amitriptyline (20/54).  A minority of patients was 
treated with muscle relaxants (17%, 9/54) or various other medications including 
lidocaine patch (19%, 10/54).  Patients used a median of 2 concurrent medications 
(range, 1 – 6) for pain management.  Other methods of pain control included spinal 
block (5 patients), radiofrequency lesioning (2 patients), and a transcutaneous electrical 
nerve stimulator (TENS) unit (1 patient).  No patients were treated with chemotherapy. 
 
Comorbid Conditions 
 Eleven patients (12.6%) were diagnosed with 16 malignancies.  At initial 
pathologic review, three patients were diagnosed with MPNST and 1 patient with 
spindle cell carcinoma.  Upon further review by one author with expertise in NF-related 
pathology (ASR), the pathologic diagnosis was revised in all 4 cases.  Two cases of 
MPNST were re-classified as cellular schwannomas based on their histological features 
and their diffuse, marked expression of S100 and p16 proteins on 
immunohistochemistry (Fig. 1b-d); 1 case of MPNST was reclassified as melanoma 
based on the presence of a characteristic BRAFV600E mutation (that was also present in 
a co-existent primary skin melanoma); and 1 case of spindle cell carcinoma was not 
available for review but was presumed to be schwannoma based on the long term 
survival of the patient after diagnosis (longer than 35 years).  The remaining 
malignancies included 7 skin cancers (4 basal cell carcinomas, 2 squamous cell 
carcinomas, and 1 melanoma); 2 papillary thyroid carcinomas; 2 breast cancers (1 
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ductal carcinoma and one of unknown type) and 1 lung adenocarcinoma. 
 Fifty-two patients (60%) had cysts diagnosed clinically, pathologically, or 
radiographically.  Fifteen patients (17.2%) had visceral cysts, including renal cysts (14), 
hepatic cysts (3), and a pancreatic cyst (1).  Thirteen of 46 women in the study (28%) 
had cysts in the ovaries and/or fallopian tubes.  Other common cysts included mucus 
retention cysts in the maxillary sinuses; Baker’s, subchondral, and synovial cysts in the 
joints; and epidermal cysts on the skin. 
 Twenty-six patients (30%) received clinical diagnoses of depression, including 
18/46 women (39%) and 7/41 men (17%).  Eighteen patients (20%) reported migraines 
or frequent headaches, including 13/46 women (28%) and 5/41 men (12%).  Eleven 
patients (13%) had diagnoses of hypothyroidism and were receiving levothyroxine.  Of 
these, 10/46 (22%) were women and 1/41 (2%) was male. 
 
Discussion 
 One of the main challenges in diagnosing schwannomatosis is to differentiate it 
from NF2 or NF1.  While none of the patients in our cohort simultaneously met 
diagnostic criteria for NF1 or for NF2, careful attention to other clinical manifestations 
remains essential in establishing the correct diagnosis.  Some NF2 patients may 
present with multiple peripheral schwannomas[11], making it critical to screen all 
suspected schwannomatosis patients for NF2.  Schwannomatosis is characterized by 
the presence of multiple non-vestibular, non-intradermal schwannomas whereas the 
hallmark of NF2 is the presence of bilateral vestibular schwannomas. The consensus 
diagnostic criteria and the revised diagnostic criteria address this issue by requiring 
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cranial MRI scans to exclude vestibular schwannomas.   However, a recent report from 
the Manchester group suggests that schwannomatosis patients may, in fact, develop 
unilateral vestibular schwannomas[12], further blurring the distinction between these 
two conditions.  To date, neither cataracts, epiretinal membranes, nor spinal 
ependymoma have been described at increased frequency in schwannomatosis 
patients.  Similarly, schwannomatosis must be differentiated from NF1.  The lack of 
cardinal features of NF1—skin-fold freckling, greater than 6 café-au-lait macules, 
multiple cutaneous nerve sheath tumors, and Lisch nodules—are helpful in excluding a 
diagnosis of NF1 in these patients.  Importantly, the presence of intracranial 
meningioma or cutaneous neurofibroma does not exclude a diagnosis of 
schwannomatosis. 
 This retrospective review of 87 patients describes the largest cohort of 
schwannomatosis patients to date and provides a comprehensive view of the disease 
phenotype.  Our results extend previous findings in smaller case series[8,4] and 
documents the common and uncommon features associated with schwannomatosis.  In 
our series, the high rate of peripheral schwannomas (89% of patients) and spinal 
schwannomas (74%) support a pro-active surveillance plan for schwannomatosis 
patients in which neurological symptoms and signs are investigated by MRI to identify 
tumors.  These studies can distinguish between schwannoma-related pain and other 
common causes of pain that are not related to tumors (e.g., degenerative disc disease, 
arthritis, or plantar fasciitis).  Follow-up MRI scans can be performed periodically based 
on clinical symptoms to monitor for the appearance of new tumors, changes in tumor 
size, and involvement of nearby structures.  
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In accordance with previous reports, the rate of anatomically limited disease was 
30%.[4]  However, since patients in this study did not receive whole-body MRI scans, 
asymptomatic tumors in other body regions might have been missed by regional MRI.  
Despite the high prevalence of schwannomas, the median delay in diagnosis was 7 
years in our population, indicating the need for earlier recognition of symptoms.  
 Other clinical features associated with NF2 were also present in our patients.  
Intracranial meningiomas were identified in 5% of our cohort as compared to an 
expected prevalence of about 50% in NF2 patients.[13]  These tumors usually occurred 
as solitary tumors in schwannomatosis patients whereas they are often multiple or 
confluent in NF2 patients.  The presence of a meningioma in a schwannomatosis 
patient was noted in early patient series[3,14] and recently, multigenerational families 
with meningiomas and germline SMARCB1 mutations have been described.[10,9]   
Other tumors common in NF2—spinal meningiomas and ependymomas—were not 
found in this series.  Finally, there was no common ophthalmologic pathology in 
schwannomatosis patients.  This finding contrasts with that for NF2 patients in whom 
cataracts are found in up to 80% of patients.[15]   
 Chronic pain remains the hallmark of schwannomatosis.  The majority of our 
patients (68%) experienced chronic pain, and a significant number were disabled by 
their pain.  Despite aggressive management with surgery (99%) and pain medication 
(62%), most patients did not become pain-free.  Furthermore, 20% of patients (28% of 
women and 12% of men) experienced frequent headaches, which were often described 
as “migraines”.  Whether this reflects a misattribution of non-specific pain from other 
body parts or a separate mechanism remains unclear.   Referral to an experienced pain 
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clinic is warranted for schwannomatosis patients with chronic pain. 
 Depression and anxiety are also common in schwannomatosis patients, with 
39% of women and 17% of men reporting a history of these mood disorders.  Survey 
data indicates that patients with schwannomatosis suffer impaired quality of life and 
higher rates of depression than the normal population [16].  It is likely that the stress of 
living with a chronic pain, especially pain that is often undiagnosed for years, leads to 
increased psychosocial stress on these patients.  Active surveillance for and treatment 
of mood disorders is a central aspect of patient care, and appropriate referrals to mind-
body programs and psychiatric treatment is warranted. 
 There is concern for increased risk of malignancy in patients with 
schwannomatosis, in particular for MPNST and atypical teratoid/rhabdoid tumors 
(AT/RT) since these tumors have been reported in patients with familial 
schwannomatosis.[7,8]  In our cohort, three patients were diagnosed with MPNST at 
initial pathologic review.  All 3 diagnoses were revised upon subsequent review, and 
during this process, we identified features that may cause pathologic misdiagnosis of 
schwannomatosis-related schwannomas.  In one cellular schwannoma, morphological 
features of classic schwannoma (such as Antoni A and Antoni B regions and Verocay 
bodies as seen in Fig 1A) were absent, and dense cellularity and mitoses were present. 
(Fig. 1B).  This schwannoma contained prominent hyperchromatic, atypical nuclei due 
to ancient change that was misinterpreted as early malignant transformation in a 
neurofibroma.  A second schwannoma with prominent myxoid background (myxoid 
schwannoma) was misdiagnosed as a neurofibroma (Fig. 1C).  This error led to a 
clinical diagnosis of NF1 rather than schwannomatosis in this patient, and to 
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misinterpretation of a subsequent specimen as malignant transformation of a 
neurofibroma rather than schwannoma.   In both cases, diffuse expression of S100 
protein on immunohistochemistry was helpful in highlighting the monotonous population 
of neoplastic Schwann cells composing the tumor (Fig. 1D).  As expression of p16 is 
often associated with early malignant transformation in neurofibromas, diffuse 
expression of p16 is also helpful in supporting a benign lesion in difficult cases.   A third 
MPNST was reclassified as melanoma based on the presence of a characteristic BRAF 
mutation that was also present in a pre-existing skin melanoma from the same patient.  
Distinguishing metastatic amelanotic melanoma from MPNST may be impossible based 
on histology alone as the two tumors share similar histological and 
immunohistochemical features.  However, newer molecular analysis (e.g., presence of 
characteristic BRAF mutations) can help distinguish these two entities.  Thus, in our 
series of 87 schwannomatosis patients, none were diagnosed with MPNST or AT/RT 
upon careful review.  Our results suggest that a diagnosis of MPNST in a 
schwannomatosis patient should be viewed with caution, as the pathological diagnosis 
in some of these cases may be challenging.  
 We identified clinical findings of indeterminate significance in our patient 
population. For example, our cohort had relatively high rates of lipomas, multiple 
angiolipomas, visceral cysts, orthopedic cysts, and ovarian cysts.  It is unclear whether 
this finding represents a predisposition to these types of lesions or whether it reflects 
high identification rate as a result of aggressive imaging and surgical approach for 
schwannomatosis patients.   Similarly, it is unclear whether the high rate of 
hypothyroidism in schwannomatosis patients (22% vs. 9% in the general population) 
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reflects a true association or an artifact of additional testing performed in the course of 
medical care.[17]  Additional research with other cohorts of schwannomatosis patients 
should help address these questions.   
 The main limitation of this study is its retrospective nature and single institution 
basis.  Clinical information was incomplete for some patients, particularly those referred 
to our clinic from distant locations, as these patients were most likely to seek 
consultation and diagnosis only, rather than extensive treatment and follow-up.  A multi-
center, prospective study is needed to gather more comprehensive information that is 
tailored to the clinical and research questions most pertinent to schwannomatosis.  The 
Children’s Tumor Foundation has sponsored an international schwannomatosis 
database that contains limited data on greater than 225 patients worldwide (Amanda 
Bergner, personal communication).  This valuable resource should help facilitate 
patient-based research on schwannomatosis patients over the next decade. 
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Table 1. Criteria for definite and presumptive schwannomatosis.  
 
 Research Criteria[1] 
(1997)  
Consensus Criteria[4] (2005)  Revised Clinical  Criteria[5] 
(2006)a 
Definite • Two or more 
pathologically sampled 
schwannomas lack of 
radiographic evidence of 
vestibular nerve tumor on 
an imaging study 
performed after age 18 
years 
• Age > 30 years and two or more non-
intradermal schwannomas, at least 1 with 
histologic confirmation and no evidence of 
vestibular tumor on high-quality MRI scan and 
no known constitutional NF2 mutation  OR 
• One pathologically confirmed non-vestibular 
schwannoma plus a first-degree relative who 
meets above criteria 
• Age > 30 years and two or more 
nonintradermal schwannomas, at 
least one with histologic 
confirmation  OR 
• One  pathologically confirmed 
schwannoma plus a first-degree 
relative who meets the above 
criteria 
Presumptive • Two or more 
pathologically sampled 
schwannomas without 
symptoms of eight nerve 
dysfunction at age > 30 
years  OR 
•  Two or more 
pathologically sampled 
schwannomas in an 
anatomically limited 
distribution without 
symptoms of eighth nerve 
dysfunction at any age 
• Age < 30 years and two or more non-
intradermal schwannomas, at least 1 with 
histologic confirmation and no evidence of 
vestibular tumor on high quality MRI scan and 
no known constitutional NF2 mutation  OR 
• Age > 45 years and two or more non-
intradermal schwannomas, at least 1 with 
histologic confirmation and no symptoms of 8th 
nerve dysfunction and no known constitutional 
NF2 mutation  OR 
• Radiographic evidence of a non-vestibular 
schwannoma and first degree relative meeting 
criteria for definite schwannomatosis 
• Age < 30 years and two or more 
nonintradermal schwannomas, at 
least one with histologic 
confirmation  OR 
• Age > 45 years and two or more 
nonintradermal schwannomas, at 
least one with histologic 
confirmation  OR 
• Radiographic evidence of a 
schwannoma and first-degree 
relative meeting the criteria for 
definite schwannomatosis 
 
a For the revised clinical criteria, all patients must not fulfill any of the existing sets of diagnostic criteria for NF2 and have no 
evidence of vestibular schwannoma on high-quality MRI scan, no first-degree relative with NF2, and no known constitutional NF2 
mutation.  
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Figure 1.  Histological misdiagnosis of schwannomas in a schwannomatosis patient.   
 
Panel A: hemotoxylin and eosin (H&E) stain of a schwannoma with classic histology, 
including numerous Verocay body formations. Panel B: H&E stain of a cellular 
schwannoma. The tumor is moderately cellular, with mitoses and foci of necrosis and 
patternless, lacking Antoni A/ Antoni B areas and Verocay bodies. This tumor can be 
misdiagnosed as low grade MPNST.  Panel C: H&E stain of schwannoma showing 
regions with prominent myxoid background. Myxoid schwannomas may be confused 
with neurofibromas.   Panel D:  Diffuse staining for S100 protein highlights the 
monotonous population of neoplastic Schwann cells composing the tumor; supporting 
the diagnosis of schwannoma. 
